Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study

被引:3
作者
Yao, Peng [1 ]
Gao, Qiushuang [1 ]
Wang, Ying [1 ]
Yao, Qizheng [2 ]
Zhang, Ji [1 ,3 ]
机构
[1] China Pharmaceut Univ, Dept Phys Chem, Sch Sci, Nanjing 211198, Peoples R China
[2] China Pharmaceut Univ, Dept Med Chem, Sch Pharm, Nanjing 211198, Peoples R China
[3] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 211198, Peoples R China
关键词
flexible docking; HDAC8; L-shaped inhibitors; methionine; selective inhibition; HISTONE DEACETYLASE INHIBITOR; DESIGN; CANCER; APOPTOSIS; EXPRESSION; DISCOVERY; CHEMISTRY; GROWTH; POTENT; EWALD;
D O I
10.1002/cmdc.202001004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The overexpression of histone deacetylase 8 (HDAC8) causes several diseases, and the selective inhibition of HDAC8 has been touted as a promising therapeutic strategy due to its fewer side effects. However, the mechanism of HDAC8 selective inhibition remains unclear. In this study, flexible docking and in silico mutation were used to explore the structural change of methionine (M274) during HDAC8 binding to inhibitors, along with the reason for this change. Meanwhile, steered and conventional molecular dynamics simulations were employed to explore the stability of the structural change. The findings suggest that M274 acts as a "switch" to control the exposure of the HDAC8-selective pocket. The structure of M274 changes from flipped-out to flipped-in only when L-shaped inhibitors bind to HDAC8. This structural change forms a groove that allows these inhibitors to enter the selective pocket. In other HDACs, a leucine residue replaces M274 in situ, and the same structural change is not observed. The findings reveal the mechanism of selective HDAC8 inhibition and provide guidance for the development of novel selective inhibitors.
引用
收藏
页码:1933 / 1944
页数:12
相关论文
共 68 条
[1]  
Allis D, 2002, MOL BIOL CELL, V13, p278A
[2]  
[Anonymous], BIOVIA DRAW 2016
[3]  
[Anonymous], 2016, BIOVIA Discovery Studio 2016
[4]   A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas [J].
Balasubramanian, S. ;
Ramos, J. ;
Luo, W. ;
Sirisawad, M. ;
Verner, E. ;
Buggy, J. J. .
LEUKEMIA, 2008, 22 (05) :1026-1034
[5]  
Balasubramanian S, 2010, BLOOD, V116, P1597
[6]   Increased Efficacy of Histone Methyltransferase G9a Inhibitors AgainstMYCN-Amplified Neuroblastoma [J].
Bellamy, Jacob ;
Szemes, Marianna ;
Melegh, Zsombor ;
Dallosso, Anthony ;
Kollareddy, Madhu ;
Catchpoole, Daniel ;
Malik, Karim .
FRONTIERS IN ONCOLOGY, 2020, 10
[7]   Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A [J].
Butler, Kyle V. ;
Kalin, Jay ;
Brochier, Camille ;
Vistoli, Guilio ;
Langley, Brett ;
Kozikowski, Alan P. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2010, 132 (31) :10842-10846
[8]   Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases [J].
Chakrabarti, Alokta ;
Melesina, Jelena ;
Kolbinger, Fiona R. ;
Oehme, Ina ;
Senger, Johanna ;
Witt, Olaf ;
Sippl, Wolfgang ;
Jung, Manfred .
FUTURE MEDICINAL CHEMISTRY, 2016, 8 (13) :1609-1634
[9]   HDAC8: a multifaceted target for therapeutic interventions [J].
Chakrabarti, Alokta ;
Oehme, Ina ;
Witt, Olaf ;
Oliveira, Guilherme ;
Sippl, Wolfgang ;
Romier, Christophe ;
Pierce, Raymond J. ;
Jung, Manfred .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (07) :481-492
[10]   Accelerated CDOCKER with GPUs, Parallel Simulated Annealing, and Fast Fourier Transforms [J].
Ding, Xinqiang ;
Wu, Yujin ;
Wang, Yanming ;
Vilseck, Jonah Z. ;
Brooks, Charles L., III .
JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2020, 16 (06) :3910-3919